TherapeuticsMD (NASDAQ:TXMD) Issues Earnings Results, Beats Expectations By $6.13 EPS

TherapeuticsMD (NASDAQ:TXMD) released its quarterly earnings data on Tuesday. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13, FiscalAI reports. TherapeuticsMD had a return on equity of 0.32% and a net margin of 5.34%.The business had revenue of $0.87 million during the quarter, compared to the consensus estimate of $19.77 million.

TherapeuticsMD Price Performance

Shares of NASDAQ TXMD remained flat at $2.07 during midday trading on Tuesday. 14,514 shares of the stock were exchanged, compared to its average volume of 50,144. TherapeuticsMD has a 52 week low of $0.99 and a 52 week high of $2.95. The stock has a market capitalization of $23.95 million, a P/E ratio of 34.50 and a beta of 0.61. The business’s 50 day moving average is $2.04 and its 200-day moving average is $2.14.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of TherapeuticsMD in a research report on Thursday, July 2nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Citadel Advisors LLC boosted its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,273 shares of the company’s stock after acquiring an additional 19,073 shares during the period. Citadel Advisors LLC owned approximately 0.30% of TherapeuticsMD worth $36,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.